Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant COVID-19 (XBB.1.5) trimeric protein vaccine
- Development stage
- Unknown
- Lead developer
- WestVac Biopharma
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Recombinant COVID-19 (XBB.1.5) Trimeric Protein Vaccine is a monovalent protein subunit vaccine developed by WestVac BioPharma (China West) in collaboration with West China Medical Center, Sichuan University. It is designed to provide protection against the SARS-CoV-2 XBB.1.5 variant by utilizing a trimeric spike (S) protein antigen produced in Sf9 insect cells via a baculovirus expression system. Formulated with a novel adjuvant, the vaccine aims to induce robust neutralizing antibody and T-cell responses. In June 2023, it became the first XBB-specific vaccine to receive Emergency Use Authorization (EUA) in China, primarily for use as a booster dose to address the immune escape of XBB subvariants.
- Brand names
- WeiKeXinCoviccine
- Other names
- Recombinant COVID-19 (XBB.1.5) Trimeric Protein Vaccine (Sf9 Cell)WestVac XBB vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on recombinant COVID-19 (XBB.1.5) trimeric protein vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant COVID-19 (XBB.1.5) trimeric protein vaccine.